Ovid Therapeutics Inc. (OVID) shareholders
Close on Nov 17, 2026Market cap $433.56MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 19,549,271 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Sirenia Capital Management LP Joint filing with Alex Silverstein (9.90%) | 18,031,333 | 9.90% | 13G (passive) | Mar 31, 2026 |
| Michael Cho Joint filing with Affinity Asset Advisors, LLC (9.10%) | 15,635,484 | 9.10% | 13G (passive) amendment | Mar 31, 2026 |
| Affinity Asset Advisors, LLC Joint filing with Michael Cho (7.90%) | 15,143,728 | 7.90% | 13G (passive) amendment | Jun 30, 2026 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more | 13,259,735 | 9.90% | 13G (passive) | Dec 11, 2025 |
| Robin C. John Joint filing with Eventide Asset Management, LLC (7.30%), Finny Kuruvilla, M.D., Ph. D. (7.30%) | 12,773,577 | 7.30% | 13G (passive) | Mar 31, 2026 |
| Affinity Healthcare Fund, LP Joint filing with Affinity Asset Advisors, LLC (9.00%) | 12,149,166 | 9.00% | 13G (passive) | Dec 11, 2025 |
| Eventide Asset Management, LLC Joint filing with Finny Kuruvilla, M.D., Ph. D. (6.30%), Robin C. John (6.30%) | 11,812,241 | 6.30% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 10,822,672 | 5.80% | 13G (passive) | Jun 30, 2026 |
| ADAR1 Capital Management, LLC Joint filing with Daniel Schneeberger (5.10%) | 9,559,979 | 5.10% | 13G (passive) amendment | Jun 30, 2026 |
| Takeda Pharmaceutical Company Limited Joint filing with Takeda Pharmaceutical U.S.A., Inc. (9.80%) | 8,781,996 | 12.30% | 13G (passive) amendment | Dec 8, 2025 |
| Voting Shares Irrevocable Trust Joint filing with Federated Hermes, Inc. (5.94%), Thomas R. Donahue (5.94%) and 2 more | 7,737,166 | 5.94% | 13G (passive) | Dec 31, 2025 |
| Janus Henderson Group PLC | 7,114,114 | 9.99% | 13G (passive) | Nov 28, 2025 |
| Dmitry Balyasny Joint filing with Balyasny Asset Management L.P. (5.33%), Bam Gp LLC (5.33%) and 2 more | 7,029,223 | 5.33% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OVID | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 20,741,234 | 10.62% | $55.90M | New | 0.02% |
| Eventide Asset Management, LLC | 11,812,241 | 6.05% | $31.77M | +1,895,330 | 0.42% |
| BlackRock, Inc. | 10,823,480 | 5.54% | $29.12M | +9,290,197 | 0.00% |
| Ra Capital Management, L.P. | 10,500,968 | 5.38% | $28.25M | −213,032 | 0.25% |
| Affinity Asset Advisors, LLC | 10,144,562 | 5.19% | $27.29M | −491,756 | 1.23% |
| State Street Corp | 7,900,765 | 4.05% | $21.25M | +7,380,482 | 0.00% |
| Vanguard Capital Management LLC | 7,760,114 | 3.97% | $20.87M | +2,501,868 | 0.00% |
| ADAR1 Capital Management, LLC | 7,417,479 | 3.80% | $19.95M | +2,873,366 | 0.91% |
| Balyasny Asset Management L.P. | 6,719,076 | 3.44% | $18.07M | +1,186,003 | 0.02% |
| Adage Capital Partners Gp, L.L.C. | 6,163,781 | 3.16% | $16.58M | – | 0.02% |
| Federated Hermes, Inc. | 5,951,666 | 3.05% | $16.01M | +2,380,666 | 0.02% |
| Braidwell LP | 5,919,464 | 3.03% | $15.92M | New | 0.59% |
| Geode Capital Management, LLC | 4,072,653 | 2.09% | $10.96M | +2,754,562 | 0.00% |
| Silverarc Capital Management, LLC | 3,101,129 | 1.59% | $8.34M | +2,101,129 | 0.87% |
| Stempoint Capital LP | 2,417,283 | 1.24% | $6.50M | New | 1.12% |
| Ikarian Capital, LLC | 2,269,704 | 1.16% | $6.11M | −625,000 | 0.66% |
| Point72 Asset Management, L.P. | 1,945,727 | 1.00% | $5.23M | +625,117 | 0.01% |
| Sphera Funds Management Ltd. | 1,353,000 | 0.69% | $3.64M | −269,828 | 0.47% |
| Northern Trust Corp | 1,246,139 | 0.64% | $3.35M | +991,335 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,140,753 | 0.58% | $3.07M | +447,497 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 131 | 147M | 75.3% | 47 / 33 | 27 / 18 | 71M | 19M |
| Q1 2026 | 103 | 105M | 53.8% | 30 / 33 | 20 / 10 | 53M | 7M |
| Q4 2025 | 84 | 62M | 31.6% | 20 / 25 | 24 / 13 | 42M | 8M |
| Q3 2025 | 81 | 36M | 18.5% | 25 / 18 | 23 / 14 | 11M | 10M |
| Q2 2025 | 71 | 36M | 18.4% | 17 / 16 | 22 / 27 | 4M | 15M |
| Q1 2025 | 82 | 46M | 23.8% | 10 / 20 | 28 / 9 | 5M | 6M |
| Q4 2024 | 82 | 48M | 24.4% | 14 / 24 | 21 / 7 | 3M | 4M |
| Q3 2024 | 75 | 48M | 24.5% | 10 / 31 | 15 / 8 | 9M | 4M |
| Q2 2024 | 74 | 47M | 24.3% | 14 / 22 | 25 / 21 | 5M | 9M |
| Q1 2024 | 81 | 52M | 26.6% | 12 / 29 | 22 / 8 | 2M | 4M |
| Q4 2023 | 77 | 53M | 27.4% | 17 / 25 | 17 / 3 | 12M | 0M |
| Q3 2023 | 64 | 42M | 21.7% | 5 / 18 | 20 / 9 | 2M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
69 funds held OVID in Q2 2026, 72% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of OVID | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,653,216 | 2.89% | $15.21M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 4,920,517 | 2.52% | $13.24M | 0.12% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,885,284 | 1.99% | $10.45M | 0.01% | Jun 30, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 2,380,666 | 1.22% | $5.29M | 0.19% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,952,622 | 1.00% | $5.25M | 0.01% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 1,934,257 | 0.99% | $5.20M | 0.29% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,676,723 | 0.86% | $3.72M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 1,214,167 | 0.62% | $3.27M | 0.02% | Jun 30, 2026 |
| Nuveen Equity Index Fund | 646,552 | 0.33% | $1.44M | 0.00% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 613,458 | 0.31% | $1.67M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 514,160 | 0.26% | $1.38M | 0.09% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 372,024 | 0.19% | $825.89K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 286,234 | 0.15% | $769.97K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 215,714 | 0.11% | $588.90K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 203,812 | 0.10% | $452.46K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jeremy M. Levin | Executive Chairman, Director | 3,770,509 | 1.93% | Mar 25, 2026 |
| Margaret A. Alexander | President and CEO, Director | 61,750 | 0.03% | Mar 2, 2026 |
| Charles Ross Carter | Chief Financial Officer | 44,375 | 0.02% | Jul 8, 2026 |
| Jeffrey A. Rona | CBFO | 156,313 | 0.08% | Mar 2, 2026 |
| Anna Greka | Director | – | – | Jun 17, 2026 |
| Bart Friedman | Director | 8,789 | 0.00% | Apr 9, 2026 |
| Stelios Papadopoulos | Director | 217,578 | 0.11% | Apr 9, 2026 |
| Kevin Joseph Fitzgerald | Director | 17,578 | 0.01% | Apr 9, 2026 |
| Karen Bernstein | Director | 20,000 | 0.01% | Mar 2, 2026 |
| Barbara Gayle Duncan | Director | – | – | Mar 2, 2026 |
| Pharmaceutical Co Ltd Takeda | 10% owner | 7,531,996 | 3.86% | Dec 9, 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10% owner | 8,781,996 | 4.50% | Dec 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Charles Ross Carter Chief Financial Officer | Jul 6, 2026 | Award | +50,000 | – | – | 94,375 |
| Kevin Joseph Fitzgerald Director | Apr 7, 2026 | Award | +17,578 | $2.56 | $45.00K | 17,578 |
| Stelios Papadopoulos Director | Apr 7, 2026 | Award | +17,578 | $2.56 | $45.00K | 217,578 |
| Bart Friedman Director | Apr 7, 2026 | Award | +8,789 | $2.56 | $22.50K | 8,789 |
| Jeremy M. Levin Executive Chairman, Director | Mar 23, 2026 | Option exercise | +47,333 | $1.40 | $66.27K | 3,735,048 |
| Jeffrey A. Rona CBFO | Feb 26, 2026 | Award | +68,125 | – | – | 156,313 |
| Margaret A. Alexander President and CEO, Director | Feb 23, 2026 | Sale | −11,656 | $1.45 | $16.90K | 61,750 |
| Jeffrey A. Rona CBFO | Feb 23, 2026 | Sale | −8,541 | $1.45 | $12.38K | 88,188 |
| Jeremy M. Levin CEO, Director | Dec 15, 2025 | Conversion | +71,000 | – | – | 3,687,715 |
| Takeda Pharmaceuticals U.S.A., Inc. 10% owner | Dec 8, 2025 | Conversion | +1,250,000 | – | – | 7,000,000 |
| Jeffrey A. Rona CBFO | Feb 26, 2025 | Sale | −3,902 | $0.56 | $2.19K | 67,973 |
| Margaret A. Alexander President and COO | Feb 26, 2025 | Sale | −5,279 | $0.56 | $2.96K | 73,406 |
| Jeffrey A. Rona CBFO | Feb 20, 2025 | Award | +43,750 | – | – | 71,875 |
| Margaret A. Alexander President and COO | Feb 20, 2025 | Award | +43,750 | – | – | 78,685 |
| Margaret A. Alexander President and COO | Jan 27, 2025 | Buy | +6,810 | $0.73 | $4.97K | 34,935 |
| Jeremy M. Levin CEO, Director | Mar 18, 2024 | Buy | +18,248 | $2.76 | $50.36K | 3,616,715 |
| Jason Tardio Chief Operating Officer | Feb 22, 2024 | Award | +28,125 | – | – | 28,125 |
| Jeffrey A. Rona CBFO | Feb 22, 2024 | Award | +28,125 | – | – | 28,125 |
| Thomas Michael Perone General Counsel, Secretary | Feb 22, 2024 | Award | +28,125 | – | – | 28,125 |
| Jeremy M. Levin CEO, Director | Dec 4, 2023 | Gift | −573,275 | – | – | 4,171,742 |
| Jeremy M. Levin CEO, Director | Dec 4, 2023 | Gift | −573,275 | – | – | 3,598,467 |
| Jason Tardio Chief Operating Officer | Sep 12, 2022 | Sale | −17,344 | $2.15 | $37.29K | 0 |
| Pharmaceutical Co Ltd Takeda 10% owner | Jul 1, 2022 | Other | +5,750,000 | – | – | 5,750,000 |
| Pharmaceutical Co Ltd Takeda 10% owner | Jul 1, 2022 | Other | −5,750,000 | – | – | 0 |
| Amit Rakhit President and CMO | Jul 14, 2021 | Sale | −34,017 | $3.71 | $126.20K | 726,823 |
| Amit Rakhit President and CMO | Jul 14, 2021 | Option exercise | +34,017 | $1.89 | $64.29K | 760,840 |
| Jeremy M. Levin CEO, Director, 10% owner | Aug 28, 2020 | Buy | +8,488 | $5.84 | $49.57K | 5,792,530 |
| Pharmaceutical Co Ltd Takeda 10% owner | Oct 8, 2019 | Buy | +2,000,000 | $2.50 | $5.00M | 5,750,000 |
| Jeremy M. Levin CEO, Director, 10% owner | Oct 8, 2019 | Buy | +60,000 | $2.50 | $150.00K | 4,736,529 |
| Jeremy M. Levin CEO, Director | Sep 20, 2019 | Gift | −465,116 | – | – | 0 |
| Karen Bernstein Director | Feb 26, 2019 | Buy | +10,000 | $2.02 | $20.20K | 20,000 |
| Jeremy M. Levin CEO, Director, 10% owner | Feb 22, 2019 | Buy | +75,000 | $2.00 | $150.00K | 4,676,529 |
| Karen Bernstein Director | Aug 14, 2018 | Buy | +10,000 | $6.23 | $62.30K | 10,000 |
| Douglas E. Williams Director | Aug 14, 2018 | Buy | +5,000 | $6.49 | $32.45K | 5,000 |
| Jeremy M. Levin CEO, Director, 10% owner | Aug 25, 2017 | Buy | +15,334 | $7.15 | $109.64K | 4,601,529 |
| Jeremy M. Levin CEO, Director, 10% owner | May 10, 2017 | Conversion | +35,461 | – | – | 35,461 |
| Jeremy M. Levin CEO, Director, 10% owner | May 10, 2017 | Conversion | +400,150 | – | – | 4,586,195 |
| Matthew During President and CSO, Director, 10% owner | May 10, 2017 | Conversion | +28,245 | – | – | 4,307,314 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ovid Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 476,759 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jeffrey A. Rona Affiliated Stockholder | Aug 24, 2026 | 325,000 | $910.00K | Aug 24, 2026 | Stock Option Exercise |
| Jeffrey A. Rona Affiliated Stockholder | Aug 14, 2026 | 150,000 | $420.00K | Aug 14, 2026 | ESPP Purchase |
See a number that looks wrong?